Prevention of sudden death for patients with cardiomyopathies another step forward.

It has now been 30 years since the implantable cardioverterefibrillator (ICD) was introduced to the cardiovascular ommunity for the prevention of sudden cardiac death 1). Perhaps it is no longer common knowledge that the efibrillator was conceived and initially developed 40 ears ago by Drs. Michel Mirowski and Morton Mower, ot in an eminent medical institution with the robust upport of industry and the National Institutes of Health, ut rather in the basement of a small, private hospital (Sinai ospital, Baltimore, Maryland), initially with no formal unding. This entirely novel concept was initially met with ubstantial skepticism and even antagonism (2), but evenually moved forward, driven by the vision of Mirowski and ower, until it became the acknowledged treatment to